Compumedics Past Earnings Performance

Past criteria checks 0/6

Compumedics's earnings have been declining at an average annual rate of -20.6%, while the Medical Equipment industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 5.5% per year.

Key information

-20.6%

Earnings growth rate

-20.7%

EPS growth rate

Medical Equipment Industry Growth5.8%
Revenue growth rate5.5%
Return on equity-1.9%
Net Margin-0.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Compumedics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CHIA:CMP Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24500216
31 Mar 24500206
31 Dec 23501196
30 Sep 2347-2196
30 Jun 2343-6205
31 Mar 2342-6196
31 Dec 2241-6196
30 Sep 2240-2175
30 Jun 22391154
31 Mar 22371154
31 Dec 21340145
30 Sep 21350145
30 Jun 21361144
31 Mar 2135-2154
31 Dec 2035-5153
30 Sep 2035-5154
30 Jun 2035-6154
31 Mar 2038-1154
31 Dec 19413155
30 Sep 19414155
30 Jun 19424145
31 Mar 19413146
31 Dec 18403146
30 Sep 18383135
30 Jun 18373135
31 Mar 18362135
31 Dec 17342135
30 Sep 17342135
30 Jun 17341136
31 Mar 17351126
31 Dec 16362126
30 Sep 16372126
30 Jun 16383126
31 Mar 16363125
31 Dec 15353124
30 Sep 15342115
30 Jun 15332115
31 Mar 15332115
31 Dec 14321116
30 Sep 14311115
30 Jun 14311105
31 Mar 14300105

Quality Earnings: CMP is currently unprofitable.

Growing Profit Margin: CMP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CMP is unprofitable, and losses have increased over the past 5 years at a rate of 20.6% per year.

Accelerating Growth: Unable to compare CMP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CMP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.7%).


Return on Equity

High ROE: CMP has a negative Return on Equity (-1.86%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 09:23
End of Day Share Price 2025/01/16 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Compumedics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ian MartinNew Street Research LLP
Paul JenszPAC Partners Securities Pty. Ltd.
Stephen ScottTaylor Collison Limited